Impact of Metformin on Cancer Biomarkers in Non-Diabetic Cancer Patients: A Systematic Review and Meta-Analysis of Clinical Trials
Authors:
- Tahereh FarkhondehTFTahereh Farkhondeh
- Alireza AmirabadizadehAAAlireza Amirabadizadeh
- Hamed AramjooHAHamed Aramjoo
- Silvia LlorensSilvia Llorens
- Babak RoshanravanBRBabak Roshanravan
- Farhad SaeediFSFarhad Saeedi
- Marjan TalebiMTMarjan Talebi
- Mehdi ShakibaeiMehdi Shakibaei
- Saeed SamarghandianSSSaeed Samarghandian
Open Access
- 6 April 2021
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 28 (2) , 1412-1423
Abstract
Introduction: Our aim was to investigate and evaluate the influence of metformin on cancer-related biomarkers in clinical trials. Methods: This systematic study was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Major databases, including Scopus, Web of Sciences, PubMed, Ovid-Medline, and Cochrane, were systematically reviewed by February 2020. Clinical trials investigating metformin effects on the evaluation of homeostatic models of insulin resistance (HOMA-IR), Ki-67, body mass index (BMI), fasting blood sugar (FBS), and insulin were selected for further analysis. Quality assessment was performed with version 2 of the Cochrane tool for determining the bias risk for randomized trials (RoB 2). Heterogeneity among the included studies was assessed using the Chi-square test. After quality assessment, a random effects model was performed to summarize the data related to insulin, HOMA-IR, Ki-67, and a fixed-effect model for FBS and BMI in a meta-analysis. Results: Nine clinical trials with 716 patients with operable breast and endometrial cancer and 331 with primary breast cancer were involved in the current systematic and meta-analysis study. Systematic findings on the nine publications indicated metformin decreased insulin levels in four studies, FBS in one, BMI in two, Ki-67 in three studies, and HOMA-IR in two study. The pooled analysis indicated that metformin had no significant effect on the following values: insulin (standardized mean differences (SMD) = −0.87, 95% confidence intervals (CI) (−1.93, 0.19), p = 0.11), FBS (SMD = −0.18, 95% CI (−0.30, −0.05), p = 0.004), HOMA-IR (SMD = −0.17, 95% CI (−0.52, 0.19), p = 0.36), and BMI (SMD = −0.13, 95% CI (−0.28, 0.02), p = 0.09). Metformin could decrease Ki-67 in patients with operable endometrial cancer versus healthy subjects (SMD = 0.47, 95% CI (−1.82, 2.75), p = 30.1). According to Egger’s test, no publication bias was observed for insulin, FBS, BMI, HOMA-IR, and Ki-67. Conclusions: Patients with operable breast and endometrial cancer under metformin therapy showed no significant changes in the investigated metabolic biomarkers in the most of included study. It was also found that metformin could decrease Ki-67 in patients with operable endometrial cancer. In comparison to the results obtained of our meta-analysis, due to the high heterogeneity and bias of the included clinical trials, the present findings could not confirm or reject the efficacy of metformin for patients with breast cancer and endometrial cancer.Keywords
This publication has 34 references indexed in Scilit:
- Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancerTumor Biology, 2014
- Metformin—mode of action and clinical implications for diabetes and cancerNature Reviews Endocrinology, 2014
- Metformin Downregulates the Insulin/IGF-I Signaling Pathway and Inhibits Different Uterine Serous Carcinoma (USC) Cells Proliferation and Migration in p53-Dependent or -Independent MannersPLOS ONE, 2013
- Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPNature, 2013
- Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical TrialJournal of Clinical Oncology, 2012
- Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trialBreast Cancer Research and Treatment, 2011
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010
- Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer CellsCancer Research, 2006
- Prognostic Impact of Alterations in P-Cadherin Expression and Related Cell Adhesion Markers in Endometrial CancerJournal of Clinical Oncology, 2004